Haval Shirwan conducted his graduate studies at the University of California in Santa Barbara, CA, USA, and postdoctoral studies at California Institute of Technology in Pasadena, CA, USA. Shirwan joined the University of Louisville, in 1998, after holding academic appointments at various institutions in the United States. He is Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of microbiology and immunology, the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics, and Member of James Brown Cancer Center, University of Louisville, Louisville, KY, USA. The research focuses on the modulation of immune system for the treatment of immune‐based diseases with particular focus on type 1 diabetes, transplantation, and vaccines. He pioneered the ProtEx technology with his collaborator Doctor Esma S. Yolcu as a safe, efficient, and practical alternative to DNA‐based immune gene therapy to generate proprietary recombinant proteins with potent immune activities and use these proteins in soluble forms or displayed on the surface of cells, tissues, and organs for the development of prophylactic and therapeutic vaccines for infections, cancer, type 1 diabetes, and transplantation. This technology is protected by 16 issued patents worldwide. Shirwan is widely published (>160 peer‐reviewed papers, editorials, book chapters, and abstracts), organized and lectured at numerous national/international conferences, served on study sections for various federal and nonfederal funding agencies, and is the Executive Editor for the Journal of Clinical and Cellular Immunology and on the Editorial Board of 18 scientific journals. He is member of several national and international societies and recipient of various awards.
Biography Updated on 10 March 2014